1584148-50-4

Upstream product

• 105804-84-0 methyl 3-((2-methoxy-2-oxoethyl)amino)-3-methylbutanoate 
• 69950-44-3 anhydrous methyl 3-aminoisovalerate hydrochloride 
• 625-05-8 3-amino-3-methylbutanoic acid 
• 1584148-45-7 1-benzyl 2-methyl (Z)-4-((dimethylamino)methylene)-5,5-dimethyl-3-oxopyrrolidine-1,2-dicarboxylate 
• 1584148-42-4 1-benzyl 2-methyl 5,5-dimethyl-3-oxopyrrolidine-1,2-dicarboxylate 
• 1584148-41-3 methyl 3-(((benzyloxy)carbonyl)(2-methoxy-2-oxoethyl)amino)-3-methylbutanoate 

Downstream Products

• 1584145-94-7 N-benzyl-5,5-dimethyl-2-((tetrahydro-2H-pyran-4-yl)amino)-5H-pyrrolo[3,4-d]pyrimidine-6(7H)-carboxamide 
• 1584145-10-7 (S)-N-(2-hydroxy-1-phenylethyl)-5,5-dimethyl-2-((tetrahydro-2H-pyran-4-yl)amino)-5H-pyrrolo[3,4-d]pyrimidine-6(7H)-carboxamide 
• 1584148-52-6 6-benzyl 7-methyl 5,5-dimethyl-2-((tetrahydro-2H-pyran-4-yl)amino)-5H-pyrrolo[3,4-d]pyrimidine-6,7(7H)-dicarboxylate 

Relevant academic research and scientific papers

DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS

The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERKl and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics